Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude prospective internationale, ouverte, randomisée, de phase III comparant le 177Lu-PSMA-617 en association avec le SoC, par rapport au SoC seul, chez des patients adultes de sexe masculin atteints de mHSPC (PSMAddition)

13 octobre 2026 mis à jour par: Novartis Pharmaceuticals

Une étude ouverte, randomisée, de phase III comparant le 177Lu-PSMA-617 en association avec la norme de soins, par rapport à la norme de soins seul, chez des patients adultes de sexe masculin atteints d'un cancer de la prostate métastatique sensible aux hormones (mHSPC)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care (SOC), versus Standard of Care alone, in adult male patients with Metastatic hormone sensitive prostate cancer (mHSPC). In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy (ARDT) + Androgen Deprivation Therapy (ADT). Approximately 1126 patients will be randomized in this study. As of 31-Jan-2024, 1144 participants were enrolled in 19 countries.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Intervention / Traitement

Description détaillée

In this international, open-label, prospective, phase III study, where approximately 1126 patients with treatment naïve or minimally treated PSMA-positive mHSPC were to be randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.

The primary objective of the study was to determine whether the combination of 177Lu-PSMA-617 + SoC improved radiographic progression free survival (rPFS) over that obtained by administration of SoC alone in mHSPC patients.

The randomization was stratified according to the following three factors: disease volume (high v low), age >= 70 years (yes/no), and on Previous or planned treatment (prostatectomy or radiation) to primary (prostate) tumor (yes/no).

Planned study duration: approximately 50 months. screening period: after signing ICF, patients were assessed for eligibility and were scanned with 68Ga PSMA-11 to identify PSMA expression status. Following completion of all required screening procedures and verifying participant eligibility, the participant was randomized via the interactive response technology (IRT) system.

Amended protocol v02 included an option for participants to be enrolled into a separate long-term safety follow-up study, and China extension cohort (40 to 60 participants). Amended protocol v03 excluded China extension cohort and added a second 68Ga-PSMA-11 PET/CT scan at Radiographic progressive disease (rPD) following Blind Independent Review Committee (BIRC) confirmed rPD in both arms.

Prior treatment:

  • Up to 45 days of Luteinizing hormone releasing hormone (LHRH) agonist/antagonists was allowed prior to informed consent form (ICF) signature. If patient did not start the ADT prior randomization, ADT started as soon as possible and ideally no later than 2 weeks after randomization.
  • Up to 45 days of ARDT was allowed prior ICF signature. If patient did not start the ARDT prior randomization, ARDT started as soon as possible and ideally no later than 2 weeks after randomization. Patients received ARDT as per label instructions.

Randomization period:

The participant was randomized in a 1:1 ratio to receive Standard of Care (SoC) with or without the radioligand 177Lu-PSMA-617.

Treatment period:

Patients randomized to the investigational arm (i.e. SoC+177Lu-PSMA-617): Patients received SoC as per label instructions, after randomization, if not started earlier and in the time frame allowed by the protocol. Patients began 177Lu-PSMA-617 dosing within 14 days after randomization or as soon as possible after the product was received. 177Lu-PSMA-617 is administered at the dose of 7.4 GBq (+/- 10%), once every 6 weeks (+/- 1 week) for a planned 6 cycles.

Patients randomized to the control arm began receiving SoC as per label instructions after randomization, if not started earlier and in the time frame allowed by the protocol.

The primary endpoint of rPFS was assessed by a centralized blinded image review committee (i.e., BIRC) using radiographic images provided by the treating physician.

Participants from both arms also underwent PET/CT scan with 68GaPSMA-11 following Centrally confirmed rPD.

An end of treatment (EOT) visit will be performed when participants permanently discontinue study treatment.

Cross-over period:

After patients randomized to the SoC alone (i.e., control) arm experience radiographic progression (the rPFS event) as confirmed by BIRC, they will be allowed to cross-over to receive 177Lu-PSMA-617 +/- SoC per the discretion of the treating physician. If cross-over to 177Lu-PSMA-617 is selected, then 177Lu-PSMA-617 will be administered with the same dose/schedule as participants who were initially randomized to receive 177Lu-PSMA-617 as described above. Study cross-over participants for whom 177Lu-PSMA-617 is discontinued must have a second End of Treatment (EOT2) visit performed =< 7 days and enter the Post-treatment Follow-up.

Post-Treatment Follow-Up (Safety, Efficacy):

After treatment discontinuation, all participants will be followed for safety with a 30-day safety follow-up visit (FUP) as well as longer term safety follow-up assessments for a period of approximately 12 months.

Participants who discontinue study treatment without having progressive disease confirmed by BIRC, will continue to be assessed for efficacy (efficacy follow-up) during the post-treatment follow-up period until the occurrence of their BIRC-confirmed radiographic disease progression (rPFS) event , or if the total number of protocol-defined rPFS events has occurred triggering the primary analysis, whichever occurs first.

Survival Follow-Up:

After study treatment discontinuation, or post-treatment follow-up period discontinuation, the participant's status will be collected every 90 days (via phone calls) as part of the survival follow-up. Every effort should be made to comply with the survival follow-up schedule and ensure collection of participant survival. The survival follow-up and the study will end when the number of OS events required for final OS analysis will be reached.

Type d'étude

Interventionnel

Inscription (Réel)

1144

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Essen, Allemagne, 45147
        • Novartis Investigative Site
      • München, Allemagne, 80377
        • Novartis Investigative Site
      • Münster, Allemagne, 48149
        • Novartis Investigative Site
      • Rostock, Allemagne, 18057
        • Novartis Investigative Site
    • Bavaria
      • Würzburg, Bavaria, Allemagne, 97080
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne, North Rhine-Westphalia, Allemagne, 50937
        • Novartis Investigative Site
      • Brussels, Belgique, 1200
        • Novartis Investigative Site
      • Ghent, Belgique, 9000
        • Novartis Investigative Site
    • British Columbia
      • Vancouver, British Columbia, Canada, V5Z 1M9
        • Novartis Investigative Site
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Novartis Investigative Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Novartis Investigative Site
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Novartis Investigative Site
      • Montreal, Quebec, Canada, H3T 1E2
        • Novartis Investigative Site
      • Montreal, Quebec, Canada, H2X 1R9
        • Novartis Investigative Site
      • Québec, Quebec, Canada, G1R 2J6
        • Novartis Investigative Site
      • Sherbrooke, Quebec, Canada, J1H 5N4
        • Novartis Investigative Site
      • Beijing, Chine, 100036
        • Novartis Investigative Site
      • Guangzhou, Chine, 510060
        • Novartis Investigative Site
      • Shanghai, Chine, 200080
        • Novartis Investigative Site
      • Shanghai, Chine, 200032
        • Novartis Investigative Site
      • Shanghai, Chine, 200025
        • Novartis Investigative Site
      • Tianjin, Chine, 300300
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, Chine, 210029
        • Novartis Investigative Site
      • Nanjing, Jiangsu, Chine, 210006
        • Novartis Investigative Site
    • Shanxi
      • Xian, Shanxi, Chine, 710032
        • Novartis Investigative Site
    • Sichuan
      • Chengdu, Sichuan, Chine, 610041
        • Novartis Investigative Site
      • Seoul, Corée du Sud, 03080
        • Novartis Investigative Site
      • Seoul, Corée du Sud, 05505
        • Novartis Investigative Site
      • Seoul, Corée du Sud, 03722
        • Novartis Investigative Site
      • Copenhagen, Danemark, 2100
        • Novartis Investigative Site
      • Barcelona, Espagne, 08035
        • Novartis Investigative Site
      • Barcelona, Espagne, 08036
        • Novartis Investigative Site
      • Madrid, Espagne, 28041
        • Novartis Investigative Site
      • Madrid, Espagne, 28034
        • Novartis Investigative Site
      • Madrid, Espagne, 28046
        • Novartis Investigative Site
      • Madrid, Espagne, 28040
        • Novartis Investigative Site
      • Madrid, Espagne, 28222
        • Novartis Investigative Site
      • Valencia, Espagne, 46026
        • Novartis Investigative Site
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Espagne, 08907
        • Novartis Investigative Site
      • Sabadell, Barcelona, Espagne, 08208
        • Novartis Investigative Site
    • Murcia
      • El Palmar, Murcia, Espagne, 30120
        • Novartis Investigative Site
      • Bordeaux, France, 33075
        • Novartis Investigative Site
      • Clermont-Ferrand, France, 63011
        • Novartis Investigative Site
      • Lyon, France, 69373
        • Novartis Investigative Site
      • Montpellier, France, 34298
        • Novartis Investigative Site
      • Nantes, France, 44093
        • Novartis Investigative Site
      • Paris, France, 75015
        • Novartis Investigative Site
      • Paris, France, 75018
        • Novartis Investigative Site
      • Strasbourg, France, 67000
        • Novartis Investigative Site
      • Vandœuvre-lès-Nancy, France, 54511
        • Novartis Investigative Site
      • Villejuif, France, 94800
        • Novartis Investigative Site
      • Chiba, Japon, 2608717
        • Novartis Investigative Site
      • Fukuoka, Japon, 8128582
        • Novartis Investigative Site
      • Fukuoka, Japon, 8110213
        • Novartis Investigative Site
      • Fukuoka, Japon, 8120033
        • Novartis Investigative Site
      • Fukushima, Japon, 9601295
        • Novartis Investigative Site
      • Kyoto, Japon, 6068507
        • Novartis Investigative Site
      • Okayama, Japon, 7008558
        • Novartis Investigative Site
      • Yamagata, Japon, 9909585
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japon, 4668560
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Japon, 0608648
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, Japon, 6500047
        • Novartis Investigative Site
    • Kanagawa
      • Yokohama, Kanagawa, Japon, 2360004
        • Novartis Investigative Site
    • Kumamoto
      • Kumamoto, Kumamoto, Japon, 8608556
        • Novartis Investigative Site
    • Osaka
      • Suita, Osaka, Japon, 5650871
        • Novartis Investigative Site
    • Saitama
      • Kitaadachi-gun, Saitama, Japon, 3620806
        • Novartis Investigative Site
    • Tokyo
      • Bunkyo Ku, Tokyo, Japon, 1138431
        • Novartis Investigative Site
      • Chuo Ku, Tokyo, Japon, 1040045
        • Novartis Investigative Site
      • Linz, L'Autriche, 4020
        • Novartis Investigative Site
      • Vienna, L'Autriche, 1090
        • Novartis Investigative Site
    • Tyrol
      • Innsbruck, Tyrol, L'Autriche, 6020
        • Novartis Investigative Site
      • Nijmegen, Pays-Bas, 6525 GA
        • Novartis Investigative Site
      • Utrecht, Pays-Bas, 3584 CX
        • Novartis Investigative Site
    • Limburg
      • Maastricht, Limburg, Pays-Bas, 6229 HX
        • Novartis Investigative Site
    • South Holland
      • Delft, South Holland, Pays-Bas, 2625 AD
        • Novartis Investigative Site
      • Krakow, Pologne, 30-688
        • Novartis Investigative Site
      • Warsaw, Pologne, 02-781
        • Novartis Investigative Site
    • Silesian Voivodeship
      • Gliwice, Silesian Voivodeship, Pologne, 44-101
        • Novartis Investigative Site
      • Belfast, Royaume-Uni, BT9 7AB
        • Novartis Investigative Site
      • Cambridge, Royaume-Uni, CB2 0QQ
        • Novartis Investigative Site
      • Glasgow, Royaume-Uni, G12 0YN
        • Novartis Investigative Site
      • London, Royaume-Uni, NW3 2QG
        • Novartis Investigative Site
      • London, Royaume-Uni, EC1A 7BE
        • Novartis Investigative Site
      • London, Royaume-Uni, NW1 2BU
        • Novartis Investigative Site
      • Middlesbrough, Royaume-Uni, TS4 3BW
        • Novartis Investigative Site
    • Surrey
      • Sutton, Surrey, Royaume-Uni, SM2 5PT
        • Novartis Investigative Site
      • Singapore, Singapour, 119228
        • Novartis Investigative Site
      • Singapore, Singapour, 168583
        • Novartis Investigative Site
      • Bern, Suisse, 3010
        • Novartis Investigative Site
      • Lausanne, Suisse, 1011
        • Novartis Investigative Site
      • Gothenburg, Suède, 413 45
        • Novartis Investigative Site
      • Lund, Suède, 221 85
        • Novartis Investigative Site
      • Stockholm, Suède, 17176
        • Novartis Investigative Site
      • Taipei, Taïwan, 10002
        • Novartis Investigative Site
      • Taoyuan, Taïwan, 33305
        • Novartis Investigative Site
      • Olomouc, Tchéquie, 779 00
        • Novartis Investigative Site
      • Prague, Tchéquie, 150 06
        • Novartis Investigative Site
    • Arizona
      • Scottsdale, Arizona, États-Unis, 85259
        • Mayo Clinic Arizona
    • California
      • La Jolla, California, États-Unis, 92093-0658
        • University of California San Diego - Moores Cancer Center
      • Los Angeles, California, États-Unis, 90073
        • VA Greater LA Healthcare System
      • Los Angeles, California, États-Unis, 90095
        • University of California LA
      • Orange, California, États-Unis, 92868
        • Univ Cali Irvine ALS Neuromuscular
      • Orange, California, États-Unis, 92686
        • St. Joseph Hospital
      • Palo Alto, California, États-Unis, 94304
        • Stanford University Medical Center
      • Palo Alto, California, États-Unis, 94304-1207
        • VA Palo Alto Health Care System
      • Santa Barbara, California, États-Unis, 93105
        • Sansum Clinic
      • Santa Monica, California, États-Unis, 90404
        • Providence Saint Johns Health Ctr
    • Colorado
      • Aurora, Colorado, États-Unis, 80045
        • Univ Of Color Anschutz Med Center
      • Denver, Colorado, États-Unis, 80218
        • Rocky Mountain Cancer Centers
    • Connecticut
      • Hartford, Connecticut, États-Unis, 06102
        • Hartford Hospital
    • District of Columbia
      • Washington D.C., District of Columbia, États-Unis, 20007
        • Georgetown University-Lombardi Cancer Center
      • Washington D.C., District of Columbia, États-Unis, 20422
        • VA Medical Center
    • Florida
      • Jacksonville, Florida, États-Unis, 32256
        • Cancer Specialists of North Florida
      • Jacksonville, Florida, États-Unis, 32224
        • Mayo Clinic Jacksonville
      • Miami, Florida, États-Unis, 33173
        • Baptist Health South
      • Miami, Florida, États-Unis, 33136
        • University Of Miami
      • Panama City, Florida, États-Unis, 32405
        • Florida Cancer Affiliates
    • Georgia
      • Athens, Georgia, États-Unis, 30607
        • University Cancer and Blood Center LLC
    • Hawaii
      • Honolulu, Hawaii, États-Unis, 96813
        • The Queens Medical Centre
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Northwestern University
      • Chicago, Illinois, États-Unis, 60612
        • Rush University Medical Center
      • Chicago, Illinois, États-Unis, 60637
        • University of Chicago
      • Hines, Illinois, États-Unis, 60141
        • Hines VA Hospital
    • Indiana
      • Fort Wayne, Indiana, États-Unis, 46845
        • Parkview Research Center
      • Indianapolis, Indiana, États-Unis, 46202
        • Indiana University
    • Louisiana
      • New Orleans, Louisiana, États-Unis, 70121
        • Ochsner Clinic Foundation
      • New Orleans, Louisiana, États-Unis, 70112
        • Tulane Cancer Center
    • Maryland
      • Baltimore, Maryland, États-Unis, 21231
        • Sidney Kimmel CCC At JH
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02115
        • Dana Farber Cancer Institute
    • Michigan
      • Ann Arbor, Michigan, États-Unis, 48109
        • Uni Of Michigan Health System
      • Royal Oak, Michigan, États-Unis, 48073-6769
        • Corewell Health William Beaum Hosp
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55455
        • University of Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Mayo Clinic Rochester
    • Mississippi
      • Jackson, Mississippi, États-Unis, 39216
        • University of Mississippi Med Ctr
    • Missouri
      • St Louis, Missouri, États-Unis, 63106
        • VA St Louis Health Care System
      • St Louis, Missouri, États-Unis, 63110
        • Wash U School of Medicine
      • St Louis, Missouri, États-Unis, 63104
        • St Louis University
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68130
        • Urology Cancer Center PC
      • Omaha, Nebraska, États-Unis, 68130
        • Nebraska Cancer Specialists
    • New Mexico
      • Albuquerque, New Mexico, États-Unis, 87131-0001
        • University of New Mexico
    • New York
      • New York, New York, États-Unis, 10021
        • Weill Cornell Medical College
      • New York, New York, États-Unis, 10065
        • Memorial Sloan Kettering Cancer Ctr
      • Rochester, New York, États-Unis, 14642
        • Univ Of Rochester Cancer Ctr
      • The Bronx, New York, États-Unis, 10467
        • Montefiore Medical Center
    • North Carolina
      • Charlotte, North Carolina, États-Unis, 28203
        • Levine Cancer Institute
      • Durham, North Carolina, États-Unis, 27710
        • Duke Univ Medical Center
    • Ohio
      • Cleveland, Ohio, États-Unis, 44195
        • Cleveland Clinic Foundation
      • Columbus, Ohio, États-Unis, 43221
        • The Ohio State University Comprehensive Cancer Center
    • Oregon
      • Portland, Oregon, États-Unis, 97239
        • Oregon Health Sciences University
    • Pennsylvania
      • Hershey, Pennsylvania, États-Unis, 17033
        • Penn State Hershey Medical Center
      • Philadelphia, Pennsylvania, États-Unis, 19107
        • Thomas Jefferson Univ Hosp
      • Pittsburgh, Pennsylvania, États-Unis, 15232
        • Univ of Pittsburgh Cancer Institute
    • South Carolina
      • Myrtle Beach, South Carolina, États-Unis, 29572
        • Carolina Urologic Research Center
    • Texas
      • Amarillo, Texas, États-Unis, 79124
        • Texas Oncology
      • Dallas, Texas, États-Unis, 75216
        • Dallas VA Medical Center
      • Dallas, Texas, États-Unis, 75390-9034
        • Univ of Texas Southwest Med Center
      • Houston, Texas, États-Unis, 77030
        • MD Anderson
      • Houston, Texas, États-Unis, 77030
        • UT Health Science Center
      • San Antonio, Texas, États-Unis, 78229
        • UT Health San Antonio Mays Cancer Center
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22908
        • University of Virginia Medical Center
      • Norfolk, Virginia, États-Unis, 23502
        • Virginia Oncology Associates
      • Roanoke, Virginia, États-Unis, 24014
        • Onco Hemato Asso of SW Virginia
    • Washington
      • Seattle, Washington, États-Unis, 98122-4379
        • Swedish Medical Center
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Medical College of Wisconsin

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 100 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Homme

La description

Inclusion Criteria:

Participants eligible for inclusion in this study must meet all of the following criteria:

  1. Signed informed consent must be obtained prior to participation in the study

  2. Patients must be adults ≥18 years of age

  3. Patients must have an ECOG performance status of 0 to 2

  4. Patients must have a life expectancy >9 months as determined by the study investigator

  5. Patients must have metastatic prostate cancer with histologically or cytologically confirmed adenocarcinoma (current or prior biopsy of the prostate and/or metastatic site)

  6. Patients must have evidence of PSMA-positive disease as seen on a 68Ga-PSMA-11 PET/CT scan, and eligible as determined by the sponsor's central reader

  7. Patients must have at least one documented metastatic bone and/or soft tissue/visceral lesion documented in the following manners within 28 days prior randomization:

    1. Metastatic disease to the bone (in any distribution) visible on 99Tc-MDP bone scintigraphy on either pre-ADT scans or baseline scans AND/OR
    2. Lymph node metastases of any size or distribution. If lymph nodes are the only site of metastasis, then at least one must be at least 1.5 cm in short axis AND outside of the pelvis AND/OR
    3. Visceral metastases of any size or distribution. If a participant has a history of visceral metastases at any time prior to randomization, he should be coded as having visceral metastases at baseline (i.e., patients with visceral metastases prior to ADT that disappear at baseline will be counted as having visceral metastases and would therefore have high volume disease for stratification purposes).
  8. Patients must have adequate organ function:

    • Bone marrow reserve ANC ≥1.5 x 109/L Platelets ≥100 x 109/L Hemoglobin ≥9 g/dL
    • Hepatic Total bilirubin ≤2 x the institutional upper limit of normal (ULN). For patients with known Gilbert's Syndrome ≤3 x ULN is permitted Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤3.0 x ULN OR ≤5.0 x ULN for patients with liver metastases
    • Renal eGFR ≥ 50 mL/min/1.73m2 using the Modification of Diet in Renal Disease (MDRD) equation
  9. Albumin ≥2.5 g/dL

  10. Human immunodeficiency virus (HIV)-infected patients who are healthy and have a low risk of acquired immune deficiency syndrome (AIDS)-related outcomes can participate in this trial

  11. Patients must be:

Treatment naïve OR minimally treated with:

  • Up to 45 days of luteinizing hormone-releasing hormone (LHRH) agonist /antagonists or bilateral orchiectomy with or without first generation anti-androgen (e.g. bicalutamide, flutamide) for metastatic prostate cancer is allowed prior to ICF signature. If given, first generation anti-androgen must be discontinued prior to start of study therapy or after 45 days whatever happens first.
  • If received, prior LHRH agonist/antagonist with or without first generation anti-androgen use in the adjuvant/neo-adjuvant setting must have been discontinued > 12 months prior to ICF signature AND must not have exceeded 24 months of therapy AND must not have shown disease progression within 12 months of completing adjuvant/neo-adjuvant therapy.
  • Up to 45 days of CYP17 inhibitor or ARDT exposure for metastatic prostate cancer is allowed prior to ICF signature. No CYP17 inhibitor or ARDT exposure for earlier stages of prostate cancer is allowed.

Exclusion Criteria:

Participants meeting any of the following criteria are not eligible for inclusion in this study.

  1. Participants with rapidly progressing tumor that requires urgent exposure to taxane-based chemotherapy

  2. Any prior systemic anti-prostate cancer therapy (with the exception of the drugs listed on inclusion criteria 11), including chemotherapy, Poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors, immunotherapy or biological therapy (including monoclonal antibodies).

  3. Concurrent cytotoxicity chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological therapy or investigational therapy

  4. Previous treatment with any of the following within 6 months of randomization: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed

  5. Ongoing participation in any other clinical trial

  6. Use of other investigational drugs within 30 days prior to day of randomization

  7. Known hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes

  8. Transfusion for the sole purpose of making a participant eligible for study inclusion

  9. Participants with CNS metastases that are neurologically unstable, symptomatic, or receiving corticosteroids for the purpose of maintaining neurologic integrity. Participants with epidural disease, canal disease and prior cord involvement are allowed if those areas have been treated, are stable, and not neurologically impaired. Participants with parenchymal CNS metastasis (or a history of CNS metastasis), that have received prior therapy and are neurologically stable, asymptomatic and not receiving steroids for CNS metastases, are allowed, baseline and subsequent radiological imaging must include evaluation of the brain (magnetic resonance imaging (MRI) preferred or CT with contrast).

  10. Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free, treatment free for more than 3 years prior to randomization, or participants with adequately treated non-melanoma skin cancer, superficial bladder cancer are eligible.

  11. Concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, uncontrolled infection, known active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation. Participants with an active documented COVID-19 infection (any grade of disease severity) at time of informed consent may be included only when completely recovered (in accordance with local guidance).

  12. Active clinically significant cardiac disease defined as any of the following:

    • NYHA class 3/4 congestive heart failure within 6 months prior to ICF signature unless treated with improvement and echocardiogram or MUGA demonstrates EF > 45% with improvement in symptoms to class < 3.
    • History or current diagnosis of ECG abnormalities indicating significant risk of safety for participants in the study such as: Concomitant clinically significant cardiac arrhythmias, e.g. sustained ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third degree AV block)
    • History of familial long QT syndrome or known family history of Torsades de Pointes
    • Cardiac or cardiac repolarization abnormality, including any of the following: History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature
  13. History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study

  14. Symptomatic cord compression, or clinical or radiologic findings indicative of impending cord compression

  15. Inability to complete the study imaging procedures due to any reason (e.g., severe claustrophobia, inability to lie still for the entire imaging time, any condition that precludes raised arms position)

  16. Unmanageable concurrent bladder outflow obstruction or urinary incontinence. Note: participants with bladder outflow obstruction or urinary incontinence, which is manageable and controlled with best available standard of care (incl. pads, drainage) are allowed.

  17. Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment. A condom is required for all sexually active male participants to prevent them from fathering a child AND to prevent delivery of study treatment via seminal fluid to their partner. In addition, male participants must not donate sperm for the time period specified above. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the ICF

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: 177Lu-PSMA-617 + SoC

Participant will receive 7.4 GBq (+/- 10%) 177Lu-PSMA-617, once every 6 weeks (+/- 1 week) for a planned 6 cycles, in addition to the Standard of Care (SOC); Androgen receptor-directed therapy (ARDT) + Androgen deprivation therapy (ADT) is considered as SOC and treatment will be administered per the physician's order

administered intravenously once every 6 weeks (1 cycle) for 6 cycles

Autres noms:
  • AAA617

Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD

Autres noms:
  • AAA517

Administered orally on a continuous basis as per package insert and guideline

ADT are administered as per physician order

Comparateur actif: Standard of Care (SOC)

For participants randomized to Standard of Care arm, ARDT +ADT is considered as SOC and treatment will be administered per the physician's order

Intravenous dose of approx. 150 Megabecquerel (MBq) at screening and at time of centrally confirmed rPD

Autres noms:
  • AAA517

Administered orally on a continuous basis as per package insert and guideline

ADT are administered as per physician order

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Radiographic Progression Free Survival (rPFS)
Délai: From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months

rPFS is defined as the time of radiographic progression by Prostate Cancer Working Group 3 (PCWG3)-modified RECIST V1.1 as assessed by blinded independent central review (BIRC), or death from any cause whichever occurs first. Radiographic progression was determined by: progression in soft tissue, using RECIST 1.1 with modification outlined in PCWG3 or progression in bone disease, using bone scan and the 2+2 rule defined in the PCWG3: Rule 1 progression defined as at least 2 new lesions on first scan at week 12 and confirmed 12 weeks after with the 2 or more new lesions seen on first scan at week 12 that persist on next scan and with at least 2 additional lesions; Rule 2 progression (at week 24 or later confirmed at next scan) defined as at least 2 new lesions relative to the baseline scan observed for scans after the 18 weeks flare window, and confirmed on a subsequent scan.

From date of randomization until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approx 43 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Survival (OS) (Key Secondary Endpoint)
Délai: From date of randomization until date of death from any cause, assessed up to approx. 43 months

OS is defined as time to death for any cause

From date of randomization until date of death from any cause, assessed up to approx. 43 months
Prostate-specific Antigen 90 (PSA90) Response
Délai: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]

PSA90 response is defined as the proportion of patients who have a more/equal 90% decrease in PSA from baseline, it will be calculated at 12, 24 and 48 months.

From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)]
Time to Development of mCRPC
Délai: From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)

Time to development of mCRPC is defined as the time from date of randomization to disease progression despite androgen deprivation therapy (ADT) presenting as either a continuous rise in serum prostate-specific antigen (PSA) levels, the progression of pre existing disease, and/or the appearance of new metastases.

From date of randomization till End Of Treatment (EOT) or death, which ever happen first, assessed up to 50 months (estimated final OS analysis)
Progression Free Survival (PFS)
Délai: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)

PFS is defined as the time from date of randomization to the date of first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) or death from any cause, whichever occurs first

From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Second Progression Free Survival (PFS2)
Délai: From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)

PFS2 is defined as time from date of randomization to the first documented progression by investigator assessment (radiographic progression, clinical progression, PSA progression) on next-line therapy or death from any cause, whichever occurs first.

From date of randomization until date of second progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Change in Nadir Level of PSA Lower Than 0.2 ng/ml
Délai: From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)

Percentage of participants with PSA < 0.2 ng/mL at months 12, 24 and 48 months/

From date of randomization till 30 days safety fup, whichever occur first, assessed up to 50 months (estimated final OS analysis)
Time to Radiographic Soft Tissue Progression (TTSTP)
Délai: From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)

TTSTP is defined as time from randomization to radiographic soft tissue progression per PCWG3-modified RECIST v1.1 (Soft Tissue Rules of Prostate Cancer Working Group modified Response Evaluation Criteria in Solid Tumors Version 1.1) as assessed by Blinded Independent Central Review (BICR).

From date of randomization until date of soft tissue radiographic progression or date of death from any cause, whichever comes first, assessed up to 50 months (estimated final OS analysis)
Time to First Symptomatic Skeletal Event (SSE)
Délai: From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)

Time to SSE (TTSSE) is defined as date of randomization to the date of first new symptomatic pathological bone fracture, spinal cord compression, tumor-related orthopedic surgical intervention, requirement for radiation therapy to relieve bone pain or death from any cause, whichever occurs first.

From date of randomization till EOT or death, whichever happens first, assessed up to 50 months (estimated final OS analysis)
Overall Response Rate (ORR)
Délai: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

ORR is defined as the proportion of participants with best overall response of complete response or partial response in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.

From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Disease Control Rate (DCR)
Délai: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

DCR is defined as the proportion of participants with best overall response of complete response or partial response or Stable disease in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1.

From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Duration of Response (DOR)
Délai: From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)

DOR is defined as the duration of time between the date of first documented response (CR or PR) in soft tissue as per BIRC and according to PCWG3 modified RECIST 1.1, and the date of first documented progression or death due to any cause.

From date of randomization until date of progression or date of death from any cause, whichever come first, assessed up to 50 months (estimated final OS analysis)
Time to Response (TTR)
Délai: From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)

TTR is defined as the time from the date of randomization to the date of first documented response (CR or PR).

From date of randomization till 30 days safety fup, assessed up to 50 months (estimated final OS analysis)
Functional Assessment of Cancer Therapy - Prostate (FACT-P) Questionnaire
Délai: From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

FACT-P assesses symptoms/problems related to prostate carcinoma and its treatment. It is a combination of the FACT-General + the Prostate Cancer Subscale (PCS). The FACT-General (FACT-G) is a 27 item Quality of Life (QoL) measure that provides a total score as well as subscale scores: Physical (0-28), Functional (0-28), Social (0-28), and Emotional Well-being (0-24). The total score range is between 1-108, higher scores indicates better for total score and subscale scores. PCS is a 12-item prostate cancer subscale that asks about symptoms and problems specific to prostate cancer (Range 0-48, higher scores better). The FACT-P total score is the sum of all 5 subscale scores of the FACT-P questionnaire and ranges from 0-156. Higher scores indicate higher degree of functioning and better quality of life.

From randomization up till 30 day safety Follow-up or week 48 of long term Follow-up for patients prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Quality of Life ( EuroQoL) -5 Domain 5 Level Scale (EQ-5D-5L)
Délai: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual.

From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)
Brief Pain Inventory-short Form (PBI-SF)
Délai: From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

The BPI-SF is a publicly available instrument to assess the pain and includes severity and interference scores. BPI-SF is an 11-item self report questionnaire that is designed to assess the severity and impact of pain on daily functions of a participant. Pain severity score is a mean value for BPI-SF questions 3, 4, 5 and 6 (questions inquiring about the extent of pain, where the extent is ranked from 0 [no pain] to 10 [pain as bad as you can imagine]). Pain severity progression is defined as an increase in score of 30% or greater from baseline without decrease in analgesic use.

From screening up till 30 day safety follow-up or week 48 of long term follow up for patient prematurely discontinued, assessed up to 50 months (estimated final OS analysis)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

9 juin 2021

Achèvement primaire (Réel)

13 janvier 2025

Achèvement de l'étude (Estimé)

1 août 2028

Dates d'inscription aux études

Première soumission

19 janvier 2021

Première soumission répondant aux critères de contrôle qualité

19 janvier 2021

Première publication (Réel)

22 janvier 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 octobre 2026

Dernière vérification

1 octobre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • CAAA617C12301
  • 2023-507970-42-00 (Autre identifiant: EU CTIS)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Novartis is committed to sharing with qualified external researchers, access to participant-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .